The facility will accommodate 65 staff and connect to the secure deposition of all records associated with biopharmaceutical manufacture
In a ribbon cutting ceremony, Peter Hughes, Director of Quality at Porton Biopharma (PBL), opened a brand new suite of office accommodation that will bring together members of Quality Assurance (QA) and other departments into one integrated set of buildings.
UK-based PBL manufactures a number of biopharmaceutical products including the UK’s anthrax vaccine and Erwinase.
The new 280m2 facility will accommodate approximately 65 staff. The new building will also connect to the existing Archive building which manages the secure deposition of all the records associated with biopharmaceutical manufacture.
“Some people tend to think of pharmaceutical manufacturing only being performed by scientists or operators working in production facilities,” said Hughes. “However, Quality Assurance is a critical aspect.”
“It ensures that all the systems and processes are in place to ensure the safety and efficacy of our products.”
The building has taken six months to construct and has been designed to fit in with the existing surroundings.
It features a number of modern environmentally friendly systems, such as heat recovery pumps and grey water collection capacity.